• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

异金属钌（Ⅱ）-铼（Ⅰ）配合物的合成、表征及抗肿瘤机制研究

Synthesis, Characterization and Antitumor Mechanism Investigation of Heterometallic Ru(Ⅱ)-Re(Ⅰ) Complexes.

作者信息

Ma Xiurong, Lu Junjian, Yang Peixin, Huang Bo, Li Rongtao, Ye Ruirong

机构信息

Faculty of Life Science and Technology, Kunming University of Science and Technology, Kunming, China.

Faculty of Chemistry and Chemical Engineering, Yunnan Normal University, Kunming, China.

出版信息

Front Chem. 2022 May 27;10:890925. doi: 10.3389/fchem.2022.890925. eCollection 2022.

DOI:10.3389/fchem.2022.890925
PMID:35711955
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9196629/
Abstract

The development of heteronuclear metal complexes as potent anticancer agents has received increasing attention in recent years. In this study, two new heteronuclear Ru(Ⅱ)-Re(Ⅰ) metal complexes, Ru(bpy)LRe(CO)(DIP) and Ru(phen)LRe(CO)(DIP) [ and , L = 2-(4-pyridinyl)imidazolio[4,5-f][1,10]phenanthroline, bpy = 2,2'-bipyridine, DIP = 4,7-diphenyl-1,10-phenanthroline, phen = 1,10-phenanthroline], were synthesized and characterized. Cytotoxicity assay shows that and exhibit higher anticancer activity than cisplatin, and exist certain selectivity toward human cancer cells over normal cells. The anticancer mechanistic studies reveal that and can induce apoptosis through the regulation of cell cycle, depolarization of mitochondrial membrane potential (MMP), elevation of intracellular reactive oxygen species (ROS), and caspase cascade. Moreover, and can effectively inhibit cell migration and colony formation. Taken together, heteronuclear Ru(Ⅱ)-Re(Ⅰ) metal complexes possess the prospect of developing new anticancer agents with high efficacy.

摘要

近年来，异核金属配合物作为高效抗癌剂的开发受到了越来越多的关注。在本研究中，合成并表征了两种新型异核Ru(Ⅱ)-Re(Ⅰ)金属配合物，Ru(bpy)LRe(CO)(DIP)和Ru(phen)LRe(CO)(DIP) [L = 2-(4-吡啶基)咪唑并[4,5-f][1,10]菲咯啉，bpy = 2,2'-联吡啶，DIP = 4,7-二苯基-1,10-菲咯啉，phen = 1,10-菲咯啉]。细胞毒性试验表明，与顺铂相比，这两种配合物表现出更高的抗癌活性，并且对人癌细胞比对正常细胞具有一定的选择性。抗癌机制研究表明，这两种配合物可通过调节细胞周期、线粒体膜电位（MMP）去极化、细胞内活性氧（ROS）升高和半胱天冬酶级联反应来诱导细胞凋亡。此外，这两种配合物还能有效抑制细胞迁移和集落形成。综上所述，异核Ru(Ⅱ)-Re(Ⅰ)金属配合物具有开发高效新型抗癌剂的前景。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/edb7/9196629/76d7b6b52f74/fchem-10-890925-g009.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/edb7/9196629/ba58e565daf6/fchem-10-890925-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/edb7/9196629/e3770142d3f6/fchem-10-890925-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/edb7/9196629/4dffa8ef30e4/fchem-10-890925-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/edb7/9196629/e9f56128ab19/fchem-10-890925-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/edb7/9196629/9f9e2ad5f405/fchem-10-890925-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/edb7/9196629/19863225a609/fchem-10-890925-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/edb7/9196629/382a054b6c4e/fchem-10-890925-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/edb7/9196629/195cfaed336c/fchem-10-890925-g008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/edb7/9196629/76d7b6b52f74/fchem-10-890925-g009.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/edb7/9196629/ba58e565daf6/fchem-10-890925-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/edb7/9196629/e3770142d3f6/fchem-10-890925-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/edb7/9196629/4dffa8ef30e4/fchem-10-890925-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/edb7/9196629/e9f56128ab19/fchem-10-890925-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/edb7/9196629/9f9e2ad5f405/fchem-10-890925-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/edb7/9196629/19863225a609/fchem-10-890925-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/edb7/9196629/382a054b6c4e/fchem-10-890925-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/edb7/9196629/195cfaed336c/fchem-10-890925-g008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/edb7/9196629/76d7b6b52f74/fchem-10-890925-g009.jpg

相似文献

1
Synthesis, Characterization and Antitumor Mechanism Investigation of Heterometallic Ru(Ⅱ)-Re(Ⅰ) Complexes.异金属钌（Ⅱ）-铼（Ⅰ）配合物的合成、表征及抗肿瘤机制研究
Front Chem. 2022 May 27;10:890925. doi: 10.3389/fchem.2022.890925. eCollection 2022.
2
Heteronuclear Ru(II)-Re(I) complexes as potential photodynamic anticancer agents with anti-metastatic and anti-angiogenic activities.异核钌（II）-铼（I）配合物作为具有抗转移和抗血管生成活性的潜在光动力抗癌剂。
J Inorg Biochem. 2023 Mar;240:112090. doi: 10.1016/j.jinorgbio.2022.112090. Epub 2022 Dec 7.
3
Synthesis, characterization and antitumor mechanism investigation of ruthenium(II) polypyridyl complexes with artesunate moiety.含青蒿琥酯部分的钌（II）多吡啶配合物的合成、表征及抗肿瘤机制研究
J Biol Inorg Chem. 2021 Dec;26(8):909-918. doi: 10.1007/s00775-021-01901-8. Epub 2021 Sep 20.
4
Synthesis, characterization, molecular docking, RNA-sequence and anticancer efficacy evaluation in vitro of ruthenium(II) complexes on B16 cells.钌（II）配合物的合成、表征、分子对接、RNA 测序及体外对 B16 细胞的抗癌活性评价。
J Inorg Biochem. 2023 Oct;247:112329. doi: 10.1016/j.jinorgbio.2023.112329. Epub 2023 Jul 16.
5
Design and synthesis of new ruthenium polypyridyl complexes with potent antitumor activity in vitro.设计并合成具有体外强抗肿瘤活性的新型钌多吡啶配合物。
Spectrochim Acta A Mol Biomol Spectrosc. 2019 Sep 5;220:117132. doi: 10.1016/j.saa.2019.05.037. Epub 2019 May 15.
6
Synthesis, RNA-sequence and evaluation of anticancer efficacy of ruthenium(II) polypyridyl complexes toward HepG2 cells.钌（II）多吡啶配合物对HepG2细胞的合成、RNA测序及抗癌疗效评估
J Inorg Biochem. 2023 Jul;244:112230. doi: 10.1016/j.jinorgbio.2023.112230. Epub 2023 Apr 15.
7
Systematic evaluation of the antitumor activity of three ruthenium polypyridyl complexes.系统评价三种钌多吡啶配合物的抗肿瘤活性。
J Inorg Biochem. 2021 Dec;225:111616. doi: 10.1016/j.jinorgbio.2021.111616. Epub 2021 Sep 20.
8
Development of four ruthenium polypyridyl complexes as antitumor agents: Design, biological evaluation and mechanism investigation.四种钌多吡啶配合物作为抗肿瘤药物的研发：设计、生物学评价及作用机制研究
J Inorg Biochem. 2020 Jul;208:111104. doi: 10.1016/j.jinorgbio.2020.111104. Epub 2020 May 19.
9
Anticancer activity of ruthenium(II) plumbagin complexes with polypyridyl as ancillary ligands via inhibiting energy metabolism and GADD45A-mediated cell cycle arrest.以多吡啶为辅助配体的钌（II）白花丹醌配合物通过抑制能量代谢和GADD45A介导的细胞周期阻滞发挥抗癌活性。
Eur J Med Chem. 2022 Jun 5;236:114312. doi: 10.1016/j.ejmech.2022.114312. Epub 2022 Mar 30.
10
Novel heterobimetallic Ir(III)-Re(I) complexes: design, synthesis and antitumor mechanism investigation.新型异双核铱(III)-铼(I)配合物的设计、合成及抗肿瘤机制研究。
Dalton Trans. 2022 May 24;51(20):7907-7917. doi: 10.1039/d2dt00719c.

引用本文的文献

1
Modes of Interactions with DNA/HSA Biomolecules and Comparative Cytotoxic Studies of Newly Synthesized Mononuclear Zinc(II) and Heteronuclear Platinum(II)/Zinc(II) Complexes toward Colorectal Cancer Cells.新合成的单核锌（II）和异核铂（II）/锌（II）配合物与DNA/人血清白蛋白生物分子的相互作用模式及其对结肠癌细胞的细胞毒性比较研究
Int J Mol Sci. 2024 Mar 6;25(5):3027. doi: 10.3390/ijms25053027.
2
Cyclometalated iridium(III) complexes combined with fluconazole: antifungal activity against resistant .环金属铱(III)配合物与氟康唑联合应用：对耐药的抗真菌活性。
Front Cell Infect Microbiol. 2023 Jul 21;13:1200747. doi: 10.3389/fcimb.2023.1200747. eCollection 2023.
3

本文引用的文献

1
Correction: Microwave-assisted synthesis of polypyridyl ruthenium(ii) complexes as potential tumor-targeting inhibitors against the migration and invasion of Hela cells through G2/M phase arrest.更正：微波辅助合成聚吡啶钌（II）配合物作为潜在的肿瘤靶向抑制剂，通过G2/M期阻滞抑制Hela细胞的迁移和侵袭。
RSC Adv. 2020 Aug 26;10(52):31525. doi: 10.1039/d0ra90091e. eCollection 2020 Aug 21.
2
The role of reactive oxygen species in tumor treatment.活性氧在肿瘤治疗中的作用。
RSC Adv. 2020 Feb 24;10(13):7740-7750. doi: 10.1039/c9ra10539e. eCollection 2020 Feb 18.
3
Rhenium-guanidine complex as photosensitizer: trigger HeLa cell apoptosis through death receptor-mediated, mitochondria-mediated, and cell cycle arrest pathways.
Metal Complexes as Promising Matrix Metalloproteinases Regulators.
金属配合物作为有前景的基质金属蛋白酶调节剂。
Int J Mol Sci. 2023 Jan 9;24(2):1258. doi: 10.3390/ijms24021258.
4
Promising heterometallic compounds as anticancer agents: Recent studies in vivo.具有前景的杂金属化合物作为抗癌剂：体内的最新研究。
Curr Opin Chem Biol. 2023 Feb;72:102250. doi: 10.1016/j.cbpa.2022.102250. Epub 2022 Dec 23.
铼-胍复合物作为光敏剂：通过死亡受体介导、线粒体介导和细胞周期阻滞途径触发 HeLa 细胞凋亡。
Metallomics. 2022 May 20;14(5). doi: 10.1093/mtomcs/mfac008.
4
Targeting Mitochondrial Oxidative Phosphorylation in Glioblastoma Therapy.针对脑胶质瘤治疗中的线粒体氧化磷酸化。
Neuromolecular Med. 2022 Mar;24(1):18-22. doi: 10.1007/s12017-021-08678-8. Epub 2021 Sep 6.
5
Ruthenium(II) Diphosphine Complexes with Mercapto Ligands That Inhibit Topoisomerase IB and Suppress Tumor Growth In Vivo.含巯基配体的钌（II）二膦配合物，可抑制拓扑异构酶 IB 并在体内抑制肿瘤生长。
Inorg Chem. 2021 Sep 20;60(18):14174-14189. doi: 10.1021/acs.inorgchem.1c01539. Epub 2021 Sep 3.
6
Ruthenium Complexes as Promising Candidates against Lung Cancer.钌配合物作为治疗肺癌的潜在候选药物。
Molecules. 2021 Jul 21;26(15):4389. doi: 10.3390/molecules26154389.
7
Phosphorescent rhenium(I) complexes conjugated with artesunate: Mitochondrial targeting and apoptosis-ferroptosis dual induction.具有青蒿琥酯的发光铼（I）配合物：线粒体靶向和凋亡-铁死亡双重诱导。
J Inorg Biochem. 2021 Oct;223:111537. doi: 10.1016/j.jinorgbio.2021.111537. Epub 2021 Jul 9.
8
Phosphorescent metal complexes as theranostic anticancer agents: combining imaging and therapy in a single molecule.磷光金属配合物作为诊疗一体化抗癌剂：在单个分子中结合成像与治疗
Chem Sci. 2021 Jan 27;12(7):2357-2367. doi: 10.1039/d0sc06885c.
9
Synthesis, characterization, interactions with 9-MeG and cytotoxic activity of heterobimetallic Ru-Pt complexes bridged with 2, 2'-bipyrimidine.异双核钌-铂配合物的合成、表征、与 9-MeG 的相互作用及细胞毒性活性。
J Inorg Biochem. 2021 Jun;219:111435. doi: 10.1016/j.jinorgbio.2021.111435. Epub 2021 Mar 24.
10
Rapid Detection and Signaling of DNA Damage by PARP-1.PARP-1 对 DNA 损伤的快速检测和信号转导。
Trends Biochem Sci. 2021 Sep;46(9):744-757. doi: 10.1016/j.tibs.2021.01.014. Epub 2021 Mar 3.